Granules Inc., receives ANDA approval for prazosin hydrochloride
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
This product will be manufactured at Lupin's Goa facility in India
Flattish volume growth and subdued new launches were key factors for last month
The capsules are the generic version of the reference listed drug Mycobutin
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
The tablets are indicated for the treatment of pulmonary arterial hypertension
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
The company is moving towards complex and more differentiated products
Subscribe To Our Newsletter & Stay Updated